Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care

AIDS

Volumn 26, Issue 15, 2012, Pages 1907-1915

  Kalayjian, Robert C ^a   Lau, Bryan ^b   Mechekano, Rhoderick N ^a   Crane, Heidi M ^c   Rodriguez, Benigno ^d   Salata, Robert A ^d   Krishnasami, Zipporah ^e   Willig, James H ^e   Martin, Jeffrey N ^f   Moore, Richard D ^b   Eron, Joseph J ^g   Kitahata, Mari M ^c  

^a METROHEALTH MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

Author keywords

antiretroviral therapy; chronic kidney disease; tenofovir

Indexed keywords

AMPRENAVIR; ATAZANAVIR; EFAVIRENZ; LOPINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TENOFOVIR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHRONIC KIDNEY DISEASE; COMBINATION CHEMOTHERAPY; FEMALE; GLOMERULUS FILTRATION RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; VIRUS LOAD;

ADENINE; ADULT; AIDS-ASSOCIATED NEPHROPATHY; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HEPATITIS C; HIV SEROPOSITIVITY; HIV-1; HUMANS; INCIDENCE; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; PROPORTIONAL HAZARDS MODELS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; RITONAVIR; UNITED STATES; VIRAL LOAD;

EID: 84866737068     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328357f5ed     Document Type: Article

References (49)

1. Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD. Highly active antiretroviral therapy and the incidence of HIV-1-Associated nephropathy: a 12-year cohort study. AIDS 2004; 18:541-546. (Pubitemid 38365883)
2. Kalayjian RC, Franceschini N, Gupta SK, Szczech LA, Mupere E, Bosch RJ, et al. Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. AIDS 2008; 22:481-487. (Pubitemid 351317289)
3. Longenecker CT, Scherzer R, Bacchetti P, Lewis CE, Grunfeld C, Shlipak MG. HIV viremia and changes in kidney function. AIDS 2009; 23:1089-1096.
4. Peters PJ, Moore DM, Mermin J, Brooks JT, Downing R, Were W, et al. Antiretroviral therapy improves renal function among HIV-infected Ugandans. Kidney Int 2008; 74:925-929.
5. Reid A, Stohr W, Walker AS, Williams IG, Kityo C, Hughes P, et al. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin Infect Dis 2008; 46:1271-1281. (Pubitemid 351589914)
6. Choi AI, Shlipak MG, Hunt PW, Martin JN, Deeks SG. HIVinfected persons continue to lose kidney function despite successful antiretroviral therapy. AIDS 2009; 23:2143-2149.
7. El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, Darbyshire J, et al. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med 2008; 149:289-299.
8. Choi A, Scherzer R, Bacchetti P, Tien PC, Saag MS, Gibert CL, et al. Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons. Am J Kidney Dis 2010; 56:872-882.
9. George E, Lucas GM, Nadkarni GN, Fine DM, Moore R, Atta MG. Kidney function and the risk of cardiovascular events in HIV-1-infected patients. AIDS 2010; 24:387-394.
10. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-Transcriptase inhibitor treatment. Clin Infect Dis 2005; 40:1194-1198. (Pubitemid 40490248)
11. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-260. (Pubitemid 43113030)
12. Winston A, Amin J, Mallon P, Marriott D, Carr A, Cooper DA, et al. Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumaratecontaining highly active antiretroviral therapy. HIV Med 2006; 7:105-111.
13. Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B, Clotet B, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007; 21:1273-1281. (Pubitemid 46883481)
14. Young B, Buchacz K, Baker RK, Moorman AC, Wood KC, Chmiel J, et al. Renal function in tenofovir-exposed and tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV outpatient study. J Int Assoc Physicians AIDS Care (Chic) 2007; 6:178-187.
15. Kinai E, Hanabusa H. Progressive renal tubular dysfunction associated with long-Term use of tenofovir DF. AIDS Res Hum Retroviruses 2009; 25:387-394.
16. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-Analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010; 51:496-505.
17. Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010; 24:1667-1678.
18. Scherzer R, Estrella M, Li Y, Deeks SG, Grunfeld C, Shlipak MG. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 2012; 26:867-875.
19. Brewster UC, Perazella MA. Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. Am J Kidney Dis 2004; 44:e81-e84. (Pubitemid 39445931)
20. Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, et al. Greater tenofovir-Associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-Transcriptase inhibitor-based therapy. J Infect Dis 2008; 197:102-108. (Pubitemid 351263473)
21. Gallant JE, Moore RD. Renal function with use of a tenofovircontaining initial antiretroviral regimen. AIDS 2009; 23:1971-1975.
22. Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1: a randomized trial. Ann Intern Med 2011; 154:445-456.
23. Quiros-Roldan E, Amadasi S, Paraninfo G, Izzo I, Allegri R, Motta D, et al. The impact of gender and anchor drugs on TDF renal toxicity. J Acquir Immune Defic Syndr 2010; 55:e11-e12.
24. Crane HM, Kestenbaum B, Harrington RD, Kitahata MM. Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir. AIDS 2007; 21:1431-1439. (Pubitemid 46988003)
25. Kitahata MM, Rodriguez B, Haubrich R, Boswell S, Mathews WC, Lederman MM, et al. Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems. Int J Epidemiol 2008; 37:948-955.
26. Aberg JA, Kaplan JE, Libman H, Emmanuel P, Anderson JR, Stone VE, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:651-681.
27. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604-612.
28. Eknoyan G, Levin NW. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1-S266.
29. Levey AS, de Jong PE, Coresh J, Nahas ME, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011; 80:17-28.
30. Lee BK, Lessler J, Stuart EA. Improving propensity score weighting using machine learning. Stat Med 2010; 29:337-346.
31. Cain LE, Cole SR. Inverse probability-of-censoring weights for the correction of time-varying noncompliance in the effect of randomized highly active antiretroviral therapy on incident AIDS or death. Stat Med 2009; 28:1725-1738.
32. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000; 11:561-570. (Pubitemid 30660035)
33. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18:695-706. (Pubitemid 29126745)
34. Cosgrove CJ, Abu-Alfa AK, Perazella MA. Observations on HIV-Associated renal disease in the era of highly active antiretroviral therapy. Am J Med Sci 2002; 323:102-106. (Pubitemid 34651563)
35. Szczech LA, Edwards LJ, Sanders LL, van der Horst C, Bartlett JA, Heald AE, et al. Protease inhibitors are associated with a slowed progression of HIV-related renal diseases. Clin Nephrol 2002; 57:336-341. (Pubitemid 34477470)
36. Szczech LA, Gupta SK, Habash R, Guasch A, Kalayjian R, Appel R, et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 2004; 66:1145-1152. (Pubitemid 39121021)
37. Lucas GM, Lau B, Atta MG, Fine DM, Keruly J, Moore RD. Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. J Infect Dis 2008; 197:1548-1557. (Pubitemid 351706485)
38. Achhra AC, Amin J, Law MG, Emery S, Gerstoft J, Gordin FM, et al. Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. AIDS 2010; 24:1877-1886.
39. Baker JV, Peng G, Rapkin J, Abrams DI, Silverberg MJ, MacArthur RD, et al. CD4R count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008; 22:841-848. (Pubitemid 351563833)
40. Tong L, Phan TK, Robinson KL, Babusis D, Strab R, Bhoopathy S, et al. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother 2007; 51:3498-3504. (Pubitemid 47519335)
41. Kearney BP, Mathias A, Mittan A, Sayre J, Ebrahimi R, Cheng AK. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr 2006; 43:278-283. (Pubitemid 44674007)
42. AntoniouT,RaboudJ,ChirhinS,YoongD,GovanV,GoughK,etal. Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. HIV Med 2005; 6:284-290. (Pubitemid 41025294)
43. Wever K, van Agtmael MA, Carr A. Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr 2010; 55:78-81.
44. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Volberding PA, O'Hare AM. The impact of HIV on chronic kidney disease outcomes. Kidney Int 2007; 72:1380-1387. (Pubitemid 350126779)
45. Wyatt CM, Malvestutto C, Coca SG, Klotman PE, Parikh CR. The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-Analysis. AIDS 2008; 22:1799-1807.
46. Gupta SK, Komarow L, Gulick RM, Pollard RB, Robbins GK, Franceschini N, et al. Proteinuria, creatinine clearance, and immune activation in antiretroviral-naive HIV-infected subjects. J Infect Dis 2009; 200:614-618.
47. Fischer MJ, Wyatt CM, Gordon K, Gibert CL, Brown ST, Rimland D, et al. Hepatitis C and the risk of kidney disease and mortality in veterans with HIV. J Acquir Immune Defic Syndr 2010; 53:222-226.
48. Dauchy FA, Lawson-Ayayi S, de La Faille R, Bonnet F, Rigothier C, Mehsen N, et al. Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy. Kidney Int 2011; 80:302-309.
49. Rodriguez-Novoa S, Labarga P, Soriano V, Egan D, Albalater M, Morello J, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis 2009; 48:e108-116.